Could the next healthcare breakthrough happen outside the lab?
Scientific innovation is transforming how we treat disease, but the next true breakthrough won’t happen in a lab alone.
The real opportunity for challenger brands in healthcare
Beyond bold creative work lies a bigger opportunity: challenging the assumptions that shape how healthcare categories think, compete and serve people.
Pharma wants challenger brands. Bolder creative work. More distinctive identities. Less conventional communications.
And we're seeing encouraging signs of change. But there's a more interesting question beneath all of this: are we prepared to challenge the category itself?
A brand can look and sound different while accepting exactly the same assumptions about treatment, value and behaviour as everyone else.
That's the real opportunity for pharma. Not simply finding a different way to communicate a medicine, but having a point of view about what should change in the market around it.
Pharma knows how to find a difference. But does it know how to use it to build a distinctive brand?
Pharma is exceptionally good at identifying clinically meaningful differences. That's fundamental to how medicines are developed: defined indications, endpoints, mechanisms, populations and evidence.
Yet something interesting happens when those differences translate into marketing. Brands that are scientifically distinct can start to look, sound and behave remarkably alike. The familiar process of identifying unmet need, defining the audience, establishing positioning and communicating advantage remains important. But in increasingly crowded and consumerised categories, it may no longer be enough.
The more interesting question isn't simply, ‘What makes our brand different?’ It's ‘What should be different about this category?’
A healthcare brand has an opportunity to do more than explain why its medicine is different. It can shape how the category is understood, what people expect from care, how success is defined and what experience surrounds treatment.
The more interesting question isn't simply, ‘What makes our brand different?’ It's ‘What should be different about this category?’
Whitespace isn't the same as challenge.
We often confuse challenger thinking with creative bravery. A bold campaign, unexpected identity or provocative tone can create valuable distinction. But genuine challenger behaviour begins with a more fundamental strategic choice. What has the category accepted that should no longer be accepted?
Perhaps it's an established definition of success that overlooks what matters to people. An assumption about who should influence treatment decisions. A fragmented experience people have learned to navigate. Or a compromise in care that has become so familiar nobody questions it.
Finding whitespace means identifying a position competitors haven't occupied.
Challenger thinking means identifying something the category has normalised that deserves to change.
One creates differentiation. The other has the potential to change the basis of competition.
That's a much more demanding brief for strategy and creativity. It asks us to identify a real tension before deciding how the brand should express itself.
Challenger thinking means identifying something the category has normalised that deserves to change.
Healthcare organises people around disease. People organise health around life.
Healthcare has invested enormously in understanding people through the lens of their conditions. Disease burden, treatment barriers, clinical journeys, adherence and decision drivers are all essential areas of insight.
But people don't experience their lives as a series of neatly separated indications or treatment pathways. They bring cultural beliefs, previous treatment experiences, financial pressures, family responsibilities, digital habits and expectations shaped by the world outside healthcare.
And those expectations are changing. People increasingly expect services to recognise their circumstances, offer greater agency and respond as their needs evolve. Yet healthcare can still require people to organise their lives around the system, rather than the other way around.
What if more healthcare brands started by challenging that assumption?
Not simply asking how to move someone through an established journey but questioning whether the journey itself reflects the realities of their life.
This is where the opportunity for challenger thinking becomes particularly interesting. It can reveal tensions that conventional treatment-focused research alone may not uncover.
Regulation and creativity can work together.
There are important reasons pharmaceutical communications are highly regulated. Scientific accuracy, safety and responsibility are non-negotiable.
But working within those requirements doesn't mean sacrificing originality or strategic ambition.
Regulation defines what we can responsibly claim. It still leaves considerable room to question established assumptions, rethink treatment experiences and find more relevant ways to engage people.
Some of the most interesting challenger opportunities sit beyond product claims altogether: in how a condition is understood, how people experience care, the language used to describe success or the friction they are expected to tolerate.
Scientific responsibility and unconventional thinking can, and should, coexist.
Challenger behaviour has to extend beyond communications.
Perhaps the biggest test is whether the organisation is prepared to act on its point of view.
A brand cannot credibly challenge a category in its advertising while reinforcing the same conventions everywhere else.
- If it believes people deserve greater agency, that conviction should influence how support and experiences are designed.
- If it questions an accepted treatment journey, that should inform the evidence it explores and the partnerships it develops.
- If it believes success should be understood differently, that should influence how it measures and communicates value.
This is why challenger thinking needs to enter the brand-building process earlier, with the potential to shape the market around an innovation rather than simply differentiate within the market that already exists.
It also demands a broader role for strategy, connecting clinical understanding with culture, behaviour, experience and the commercial realities of healthcare.
A challenger idea shouldn't just change what a brand says. It should change the decisions the brand makes.
And that requires organisational conviction, not simply creative bravery.
The next generation of challenger brands in pharma won't be defined by how boldly they communicate, but by what they're prepared to question and what they're willing to do differently as a result.
Because the real test of a challenger brand isn't whether it looks different. It's whether the category thinks, chooses or behaves differently because of it.
